Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - IP002 Phase II study of carboplatin, weekly paclitaxel and bevacizumabfor advanced non-squamous cell, non- ...
Non-squamous, non-small cell lung cancer Lung cancer
Carboplatin (AUC=5) given on day1, paclitaxel (70mg/m2) given on days 1,8,15 and bevacizumab (15mg/m2) on day 1 every 4weeks until disease progression or unmanageable toxicity. Carboplatin(AUC=5) given on day1, paclitaxel(70mg/m2) given on days 1,8,15 and bevacizumab(15mg/m2) ...
Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia Phase II study of carboplatin, weekly paclitaxel and bevacizumabfor advanced non-squamous cell, non- ...
Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia Phase II study of carboplatin, weekly paclitaxel and bevacizumabfor advanced non-squamous cell, non- ...
advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia